Table 1. Screened immunogenic CTL epitopes by in vivo cytotoxicity assay using A24Tg mice.
| Peptide | A/HK/483/97(H5N1) | A/PR/8/34(H1N1) | A/Aichi/2/34(H3N2) | %Killingb |
| PA45–53 | CFMYSDFHF | CFMYSDFHF | CFMYSDFHF | 59% |
| PA130–138 | YYLEKANKI | YYLEKANKI | YYLEKANKI | 95% |
| PB1216–224 | SYLIRALTL | SYLIRALTL | GYLIRALTL | 22% |
| PB1430–438 | RYTKTTYWW | RYTKTTYWW | KYTKTTYWW | 95% |
| PB1482–490 | SYINRTGTF | SYINRTGTF | SYINKTGTF | 56% |
| PB1688–696 | MYQKCCTLF | MYQRCCNLF | MYQKCCNLF | 89% |
| PB2117–125 | TYFEKVERL | TYFERVERL | TYFDKVERL | 13% |
| PB2322–330 | SFSFGGFTF | SFSFGGFTF | SFSFGGFTF | 38% |
| PB2549–557 | TYQWIIRNW | TYQWIIRNW | TYQWVIRNW | 95% |
| M240–48 | LWILDRLFF | LWILDRLFF | LWILDRLFF | 5% |
| Tyrosinase206–214 a | AFLPWHRLF | 96% |
a
HLA-A*2402 binding high immunogenic peptide, which is unrelated to influenza virus antigen.
b
In vivo peptide specific cell reduction ratios were calculated using the formula described in Materials and Methods.